Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZ019 in Relapsed/Refractory Large B-cell Lymphoma
NCT05472610Phase 2Unknown
- Sponsor
- Shanghai Mengchao Cancer Hospital
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of BZ019 in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Mengchao Cancer Hospital. Status: unknown.
02
Drugs
BZ019
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05472610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472610.